1. Home
  2. QUIK vs CGEN Comparison

QUIK vs CGEN Comparison

Compare QUIK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuickLogic Corporation

QUIK

QuickLogic Corporation

N/A

Current Price

$9.28

Market Cap

186.1M

Sector

Technology

ML Signal

N/A

Logo Compugen Ltd.

CGEN

Compugen Ltd.

N/A

Current Price

$2.09

Market Cap

201.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QUIK
CGEN
Founded
1988
1993
Country
United States
Israel
Employees
51
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
186.1M
201.8M
IPO Year
1997
2001

Fundamental Metrics

Financial Performance
Metric
QUIK
CGEN
Price
$9.28
$2.09
Analyst Decision
Buy
Strong Buy
Analyst Count
4
5
Target Price
★ $20.00
$4.80
AVG Volume (30 Days)
181.0K
★ 229.9K
Earning Date
11-10-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $20,112,000.00
N/A
Revenue This Year
$73.22
N/A
Revenue Next Year
$18.40
$55.33
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$5.28
$1.43
52 Week High
$24.33
$3.24

Technical Indicators

Market Signals
Indicator
QUIK
CGEN
Relative Strength Index (RSI) 50.14 49.52
Support Level $8.72 $1.98
Resistance Level $10.14 $2.33
Average True Range (ATR) 0.73 0.09
MACD 0.19 0.03
Stochastic Oscillator 75.97 73.68

Price Performance

Historical Comparison
QUIK
CGEN

About QUIK QuickLogic Corporation

QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.

Share on Social Networks: